Dr. Daniele Wikoff has been appointed as new Chief Scientific Officer
ToxStrategies LLC is pleased to announce that Dr. Daniele Wikoff has been appointed as its new Chief Scientific Officer. Having had a key… read more
Latest News
Case Study of In Silico Approach to Assessing Carcinogenicity
Two toxicologists from ToxStrategies’ Pharmaceuticals Practice are among the team with a new publication concerning the use of in silico (computer modeling) approaches… read more
Congressional Briefings on CBD Regulatory Status
ToxStrategies toxicologist Dr. Rayetta Henderson served on a panel that briefed both the U.S. House and Senate on the future regulation of CBD… read more
New Publication Assessing Worker Exposure to 1,3-butadiene During Chemical Manufacturing
ToxStrategies scientists Julie Panko, Liz Mittal, and Kara Franke assessed potential worker exposures to 1,3-butadiene during chemical manufacturing and processing of the substance… read more
ToxStrategies’ Scientists Publish Acute/Short-term Inhalation Guideline for Manganese Supported by PBPK Modeling
ToxStrategies’ scientists Camarie Perry, Stephanie Vivanco, Ann Holbrow Verwiel, and Deborah Proctor conducted a regulatory and scientific literature review to develop an acute/short-term… read more
ToxStrategies is Presenting at SETAC 2023
ToxStrategies’ scientists will be participating in The Society of Environmental Toxicology and Chemistry’s (SETAC) 44th Annual Meeting this year, November 12–16, in Louisville,… read more
Announcing HEORStrategies, the newest division of ToxStrategies LLC!
HEORStrategies provides robust, strategic health economics and outcomes research (HEOR) consulting services to pharma, biotech, and medical device clients!
EpidStrategies’ Scientists are Presenting on RSV at IDWeek 2023
EpidStrategies’ scientists are recognized experts in the field of respiratory syncytial virus (RSV). Our RSV research program supported the newly-approved monoclonal antibody with… read more